Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06036316
Other study ID # 2023-A00949-36
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date January 23, 2024
Est. completion date January 23, 2026

Study information

Verified date September 2023
Source Centre Psychothérapique de Nancy
Contact Anaëlle PAJAUD
Phone 0383260863
Email Anaelle.PAJAUD@cpn-laxou.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This research concerns the study of language disorders of patients present in the spectrum of psychosis. It is indeed accepted that psychotic disorders are associated with language difficulties, which are only poorly highlighted thanks to reusable tools in clinical practice. These language disorders impact communication, and concern many linguistic domains, thus covering phonology, lexicon, semantics, morphosyntax and pragmatics. It therefore seems relevant to characterize these language disorders and to assess to what extent they interact with the other symptoms of the pathology, in particular the course of the thought disorder and the neuropsychological symptoms. In addition, this study is particularly interested in the interactions between working memory capacities and those related to syntax. It is intended for different patients suffering from psychotic disorders of different intensities, treated in the Psychotherapeutic Center of Nancy. Patients suffering from at-risk mental state (ARMS), first episode of psychosis (FEP) or schizophrenia will benefit from a complete language assessment, evaluating each domain mentioned above, on the expressive and understanding sides. The results of the language assessment will be compared with those of a control group in the same tests. They will also be analyzed with regard to the neuropsychological and psychiatric elements noted in the patient's medical file, in order to highlight possible associations between language skills, neuropsychological and psychiatric symptoms in this patient population.


Read more »

Study Design


Intervention

Read more »

Locations

Country Name City State
France Centre Psychothérapeutique de Nancy Laxou

Sponsors (1)

Lead Sponsor Collaborator
Centre Psychothérapique de Nancy

Country where clinical trial is conducted

France, 

References & Publications (1)

Majerus S. Language repetition and short-term memory: an integrative framework. Front Hum Neurosci. 2013 Jul 12;7:357. doi: 10.3389/fnhum.2013.00357. eCollection 2013. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary language assessment performance score complete speech therapy assessment evaluating each language domain. and is based on the completion of a speech therapy assessment test and on the assessment of language abilities by the experimental speech therapist. day 1
Secondary CAARMS Speech Disorganization Severity Score CAARMS: Comprehensive Assessment of At Risk Mental State day 1
Secondary Severity score for the disordered items of the course of thought of the SPI-A SPI-A:Schizophrenia Proneness Instrument day 1
Secondary Severity score for speech disorganization and formal thought disorders on the TLC Scale TLC: Thinking, Language and Communication Rating Scale day 1
Secondary Neuropsychological rating scales scores (CVLT) CVLT (California Verbal Learning test) (quantitative variable):
CVLT: number of correct recognitions
day 1
Secondary Neuropsychological rating scales scores (CVLT total) CVLT (California Verbal Learning test) (quantitative variable):
CVLT total: total number of words recalled during the test Recognition
day 1
Secondary Neuropsychological rating scales scores (Front and back spans) Front and back spans (quantitative variable) Front span size (number of digits recalled in front order) day 1
Secondary Neuropsychological rating scales scores (Front and back spans 2) Front and back spans (quantitative variable) Reverse span size (number of digits recalled in reverse order) day 1
Secondary Neuropsychological rating scales scores (TAP 1) TAP- Working Memory :Number of omissions TAP(Test of Attentional Performance) (quantitative variable) day 1
Secondary Neuropsychological rating scales scores (TAP 2) TAP- Sustained attention :Number of omissions TAP(Test of Attentional Performance) (quantitative variable) day 1
Secondary Neuropsychological rating scales scores (TAP 3) TAP- Flexibility :Number of errors TAP(Test of Attentional Performance) (quantitative variable) day 1
Secondary Neuropsychological rating scales scores (TAP 4) TAP- Incompatibility TAP(Test of Attentional Performance) (quantitative variable) day 1
Secondary Neuropsychological rating scales scores (TAP 5) TAP- Divided attention day 1
Secondary Cannabis Abuse Screening Test (CAST) score CAST: Cannabis Abuse Screening Test day 1
See also
  Status Clinical Trial Phase
Recruiting NCT05039489 - A Study on the Brain Mechanism of cTBS in Improving Medication-resistant Auditory Hallucinations in Schizophrenia N/A
Completed NCT05111548 - Brain Stimulation and Cognitive Training - Efficacy N/A
Completed NCT05321602 - Study to Evaluate the PK Profiles of LY03010 in Patients With Schizophrenia or Schizoaffective Disorder Phase 1
Completed NCT04503954 - Efficacy of Chronic Disease Self-management Program in People With Schizophrenia N/A
Completed NCT02831231 - Pilot Study Comparing Effects of Xanomeline Alone to Xanomeline Plus Trospium Phase 1
Completed NCT05517460 - The Efficacy of Auricular Acupressure on Improving Constipation Among Residents in Community Rehabilitation Center N/A
Completed NCT03652974 - Disturbance of Plasma Cytokine Parameters in Clozapine-Resistant Treatment-Refractory Schizophrenia (CTRS) and Their Association With Combination Therapy Phase 4
Recruiting NCT04012684 - rTMS on Mismatch Negativity of Schizophrenia N/A
Recruiting NCT04481217 - Cognitive Factors Mediating the Relationship Between Childhood Trauma and Auditory Hallucinations in Schizophrenia N/A
Completed NCT00212784 - Efficacy and Safety of Asenapine Using an Active Control in Subjects With Schizophrenia or Schizoaffective Disorder (25517)(P05935) Phase 3
Completed NCT04092686 - A Clinical Trial That Will Study the Efficacy and Safety of an Investigational Drug in Acutely Psychotic People With Schizophrenia Phase 3
Completed NCT01914393 - Pediatric Open-Label Extension Study Phase 3
Recruiting NCT03790345 - Vitamin B6 and B12 in the Treatment of Movement Disorders Induced by Antipsychotics Phase 2/Phase 3
Recruiting NCT05956327 - Insight Into Hippocampal Neuroplasticity in Schizophrenia by Investigating Molecular Pathways During Physical Training N/A
Terminated NCT03261817 - A Controlled Study With Remote Web-based Adapted Physical Activity (e-APA) in Psychotic Disorders N/A
Terminated NCT03209778 - Involuntary Memories Investigation in Schizophrenia N/A
Completed NCT02905604 - Magnetic Stimulation of the Brain in Schizophrenia or Depression N/A
Recruiting NCT05542212 - Intra-cortical Inhibition and Cognitive Deficits in Schizophrenia N/A
Completed NCT04411979 - Effects of 12 Weeks Walking on Cognitive Function in Schizophrenia N/A
Terminated NCT03220438 - TMS Enhancement of Visual Plasticity in Schizophrenia N/A